LabStyle Innovations,
developer of patent-pending diabetes management solution, has received a Notice
of Allowance from the U.S. Patent and Trademark Office for core patent claims
covering the company’s personalized blood glucose monitoring device.
The company’s patent pending
invention, entitled “FLUID TESTING APPARATUS AND METHODS OF USE,” specifically
relates to how the Dario™ Diabetes Management Solution blood glucose monitor
draws power from and transmits data to a smart phone through the audio jack port.
This device is designed to work in conjunction with LabStyle’s Dario™ software
application to form the overall Dario™ Diabetes Management Solution.
The issuance of the Notice
of Allowance will allow LabStyle to obtain formal U.S. patent protection in the
coming months. The company continues to seek similar patent protection in
non-U.S. jurisdictions.
LabStyle said the claims of
this invention could potentially be expanded to help manage additional chronic
diseases. Erez Raphael, LabStyle’s president and CEO, further emphasized the
importance of the Notice of Allowance.
“This is a major milestone
for our company and an important recognition of the truly novel nature of our
Dario product offering,” he stated in the news release. “Dario is the world’s first
personalized smart meter and is already changing the way people manage their
diabetes in our initial launch jurisdictions. This patent allowance validates
our efforts in developing cutting edge products that help people manage their
diabetes and thrive. Further, this patent will greatly strengthen our
competitive position in the U.S. assuming FDA approval of Dario. Importantly,
the allowed claims underscore our ownership of this technology and cover our
methodology that has been based upon our extensive database of reference
feedback, close customer collaboration, and innovative product engineering and
development. We’re extremely proud to have achieved this distinction.”
In September 2013, LabStyle
received CE mark certification for the Dario™ Blood Glucose Monitoring System
and began a global rollout in select countries. The company also filed a
Premarket Notification Application with the U.S. Food and Drug Administration
(FDA) for Dario™ in December 2013 and expects a response from the agency later
this year.
For more information, visit
www.mydario.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
